The biographer of the late legendary broadcaster Barbara Walters shared which actress should play her in a movie. Susan Page, Washington bureau chief for USA Today and author of "The Rulebreaker ...

From the very first Malayalam film that presented her on the screen in 2015, 'Premam', to Fidaa, Kali, Maari 2, Athiran, amongst others, this young actress weaves magic on the silver screen.

Shōgun's Anna Sawai has won her first Emmy Award! In doing so, she becomes the first Japanese actress to ever win an Emmy. She's the second Japanese actor to win an Emmy, following her costar ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...

(RTTNews) - Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III NATALEE trial of investigational Kisqali (ribociclib ...

Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali ...